Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03946072 · ClinicalTrials.gov registry record · NA
Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 153
- Enrollment target
NCT03946072 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 153 participants.
The verdict
NCT03946072, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 153 participants
- Enrollment target
Study Summary
This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/or premature ventricular contractions (PVCs).
Interventions
- PROCEDURE Transseptal Aortic Approach Catheter Ablation Procedure
- PROCEDURE Retrograde Aortic Approach Catheter Ablation Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2019-07-02 |
| Est. Completion | 2023-11-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03946072
The ClinicalTrials.gov registry entry for NCT03946072 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transseptal Aortic Approach Catheter Ablation Procedure is the first listed.
NCT03946072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03946072 about?
NCT03946072 is a clinical study titled "Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli". This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/...
What is the current status of trial NCT03946072?
This trial is currently completed. It is a NA study. The enrollment target is 153 participants. The study started on 2019-07-02. Estimated completion is 2023-11-25.
What interventions are being tested in trial NCT03946072?
The interventions under investigation include: Transseptal Aortic Approach Catheter Ablation Procedure (PROCEDURE), Retrograde Aortic Approach Catheter Ablation Procedure (PROCEDURE).
Who is sponsoring clinical trial NCT03946072?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.